Anti-inflammatory Activity of Mollugin on DSS-induced Colitis in Mice

Abstract

We aimed to explore the anti-inflammatory activity of mollugin extracted from Rubia cordifolia L, a traditional Chinese medicine, on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. Thirty C57BL/6 mice were divided into a control group (n=6), a model group (n=6), and three experimental groups (40, 20, 10 mg/kg of mollugin, n=6 each). DSS solution (3%) was given to mice in the model group and experimental groups from day 4 to day 10 to induce the mouse UC model. Mice in the experimental groups were intragastrically administrated mollugin from day 1 to day 10. Animals were orally given distilled water in the control group for the whole experiment time and in the model group from day 1 to day 3. The changes in colon pathology were detected by hematoxylin and eosin (HE) staining. Interleukin-1β (IL-1β) in the serum, and tumor necrosis factor-α (TNF-α) and interferon-γ (IFN) in the tissues were measured by enzyme linked immunosorbent assay. Expression levels of Toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 in the colon tissues were detected by immunohistochemistry. Results showed that mollugin could significantly reduce weight loss and the disease activity index in the DSS-induced UC mouse model. HE examinations demonstrated that mollugin treatment effectively improved the histological damage (P<0.05). The overproduction of IL-1β and TNF-α was remarkably inhibited by mollugin treatment at doses of 20 and 40 mg/kg (P<0.05). Additionally, the levels of TLR4 in colon tissues were significantly reduced in mollugin-treated groups compared with the DSS group. Our findings demonstrated that mollugin ameliorates DSS-induced UC by inhibiting the production of pro-inflammatory chemocytokines.

Keywords

mollugin / anti-inflammatory activity / DSS-induced colitis

References

[1] AzumaK, OsakiT, KurozumiS, et al.. Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease. Carbohydr Polym, 2015, 115: 448-456

[2] NgSC, TangW, ChingJY, et al.. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and colitis epidemiology study. Gastroenterology, 2013, 145(1): 158-165

[3] Al-RejaieSS, AbuohashishHM, Al-EnaziMM, et al.. Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol, 2013, 19(34): 5633-5644

[4] XiaoB, LarouiH, Ayyadurai, et al.. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials, 2013, 34(30): 7471-7482

[5] CholapraneeA, HazlewoodGS, KaplanGG, et al.. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther, 2017, 45(10): 1291-1302

[6] LeB C, RodaG, Nedeljkovic ProticM, et al.. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther, 2019, 18: 1-16

[7] Cruz-TopeteD, CidlowskiJA. One hormone, two actions: anti-and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation, 2015, 22(1-2): 20-32

[8] ChristophorouD, FunakoshiN, DunyY, et al.. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther, 2015, 41(7): 603-612

[9] GisbertJP, MarinAC, ChaparroM. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. AM J Gastroenterol, 2016, 111(5): 632-647

[10] JeonYD, BangKS, ShinMK, et al.. Regulatory effects of glycyrrhizae radix extract on DSS-induced ulcerative colitis. BMC Complement Altern Med, 2016, 16(1): 459

[11] ChenG, YangY, LiuM, et al.. Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice. J Ethnopharmacol, 2015, 166: 149-156

[12] ChenP, ZhouX, ZhangL, et al.. Anti-inflammatory effects of Huangqin tang extract in mice on ulcerative colitis. J Ethnopharmacol, 2015, 162: 207-214

[13] Chinese Pharmacopeia Commission. Phrmacopoeia of the People’s Republic of China, 2015 English ed. Chinese Medical Science Press: Beijing, China, 2015, 234–235

[14] BrijeshS, DaswaniP, TetaliP, et al.. Studies on the antidiarrhoeal activity of Aegle marmelos unripe fruit: validating its traditional usage. BMC Complement Altern Med, 2009, 9(47): 1-12

[15] JunDY, HanCR, LeeJY, et al.. Anti-adipogenic activity of 2-carbomethoxy-2,3-epoxy-3-prenyl-1,4-naphthoquinone from Rubia cordifolia L. J Med Food, 2011, 14(5): 454-461

[16] ZhuZG, JinH, YuPJ, et al.. Mollugin inhibits the inflammatory response in lipopoly saccharide-stimulated RAW264.7macrophages by blocking the Janus kinase-signal transducers and activators of transcription signaling pathway. Biol Pharm Bull, 2013, 36(03): 339-406

[17] WangZ, LiMY, MiC, et al.. Mollugin Has an AntiCancer Therapeutic Effect by Inhibiting TNF-α-Induced NF-κB Activation. Int J Mol Sci, 2017, 18(8): 1-13

[18] IdhayadhullaA, XiaL, LeeYR, et al.. Synthesis of novel and diverse mollugin analogues and their antibacterial and antioxidant activities. Bioorg Chem, 2014, 52: 77-82

[19] KimKJ, LeeJS, KwakMK, et al.. Anti-inflammatory action of mollugin and its synthetic derivatives in HT-29 human colonic epithelial cells is mediated through inhibition of NF-kappaB activation. Eur J Pharmacol, 2009, 622(1-3): 52-57

[20] ZhangL, WangH, ZhuJ, et al.. Mollugin induces tumor cell apoptosis and autophagy via the PI3K/AKT/mTOR/p70S6K and ERK signaling pathways. Biochem Biophys Res Commun, 2014, 450(1): 247-254

[21] ZhangJL, XiaoM, SongYY, et al.. Effect of the Aqueous Extract of Rubia Cordifolia’s Aerial Part on Ulcerative Colitis in Mice. Yi Yao Dao Bao Za Zhi (Chinese), 2019, 38(10): 1272-1277

[22] WangWQ, DongK, ZhouL, et al.. IL-37b gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis mice. Acta Pharmacol Sin, 2015, 36(11): 1377-1387

[23] MaJM, YinGH, LuZB, et al.. Casticin prevents DSS induced ulcerative colitis in mice through inhibitions of NF-kB pathway and ROS signaling. Phytother Res, 2018, 32(9): 1770-1783

[24] PanduranganAK, KumarSAS, DharmalingamP, et al.. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2. Pharmacogn Mag, 2014, 10: S306-310

[25] RubinDC, ShakerA, LevinMS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol, 2012, 3(107): 1-10

[26] OrdásI, EckmannL, TalaminiM, et al.. Ulcerative colitis. Lancet, 2012, 3: 1606-1619 380 (9853)

[27] VermeireBP. Treat to Target in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol, 2016, 14(1): 61-72

[28] Pineton de ChambrunG, BlancP, Peyrin-BirouletL. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol, 2016, 10(8): 915-927

[29] ChiWN, LiuZP. Research Progress of Therapeutic Drugs for Ulcerative Colitis. Med Recapitulate, 2019, 25(04): 742-747

[30] SunY, LinLJ, LinY, et al.. Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17. Int J Clin Exp Med, 2015, 8(10): 17235-17247

[31] WangK, ChenX, ShanM, et al.. Study on intestinal absorption of mollugin and purpurin in rats. Zhong guo Zhong Yao Za Zhi (Chinese), 2012, 37(12): 1855-1858

[32] KimKJ, LeeJS, KwakMK, et al.. Anti-inflammatory action of mollugin and its synthetic derivatives in HT-29 human colonic epithelial cells is medicated through inhibition of NF-kappaB activation. Eur J Pharmacol, 2009, 622(1-3): 52-57

[33] MagyariL, KovesdiE, SarlosP, et al.. Interleukin and interleukinreceptor gene polymorphisms in inflammatory bowel diseases susceptibility. World J Gastroenterol, 2014, 20(12): 3208-3222

[34] NeurathMF. Cytokines in inflammatory bowel disease. Nat Rev Immunol, 2014, 14(5): 329-342

[35] SawaY, OshitaniN, AdachiK, et al.. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med, 2003, 11(2): 175-179

[36] YangY, HeJ, SuoY, et al.. Anti-inflammatory effect of taurocholate on TNBS-induced ulcerative colitis in mice. Biomed Pharmacother, 2016, 81: 424-430

[37] BaudV, KarinM. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol, 2001, 11(9): 372-377

[38] LeppkesM, RoulisM, NeurathMF, et al.. Pleiotropic functions of TNF-α in the regulation of the intestinal epithelial response to inflammation. Int Immunol, 2014, 26(9): 509-515

[39] ChenQ, GouS, MaP, et al.. Oral administration of colitis tissue-accumulating porous nanoparticles for ulcerative colitis therapy. Int J Pharm, 2019, 557: 135-144

[40] StroberW, ZhangF, KitaniA, et al.. Proinflammatory cytokines underlying the inflammtory of Crohn’s disease. Curr Opin Gastroenterol, 2010, 26(4): 310-317

[41] SchroderK, HertzogPJ, RavasiT, et al.. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol, 2004, 75(2): 163-189

[42] JungKH, ShinD, KimS, et al.. Intratracheal Ovalbumin Administration Induces Colitis Through the IFN-gPathway in Mice. Front Immunol, 2019, 10: 530

[43] BlasiusAL, BeutlerB. Intracellular toll-like receptors. Immunity, 2019, 32(3): 305-315

[44] ChamanaraM, RashidianA, MehrSE, et al.. Melatonin ameliorates TNBS-induced colitis in rats through the melatonin receptors: involvement of TLR4/MyD88/NF-kB signalling pathway. Inflammopharmacology, 2019, 27(2): 361-371

[45] WangJP, DongLN, WangM, et al.. MiR-146a regulates the development of ulcerative colitis via mediating the TLR4/MyD88/NF-kB signalling pathway. Eur Rev Med Pharmacol Sci, 2019, 23(5): 2151-2157

[46] LiY, LiuQ, TangJH, et al.. Regulatory mechanism of mesalazine on TLR4 /MyD88 -dependent pathway in mouse ulcerative colitis model. Eur Rev Med Pharmacol Sci, 2019, 10: 530